Table 5: Prevalence values of the various T-cell subsets according to different anti-TNF therapies.

CD4CD4/CD45RACD4/CD45ROCD4/CD69CD4/HLADRCD8CD8/CD45RACD8/CD45ROCD8/HLADRCD8/CD69CD4/CD25Th1Th2Th17Treg

InfliximabMedian37.205.1143.802.574.5714.356.095.254.940.720.768.977.172.475.810
25% percentile26.551.8322.000.853.188.891.984.213.661.000.9718.408.221.834.590
75% percentile47.208.7450.205.226.7619.5319.8312.186.961.903.2119.5510.534.247.128

AdalimumabMedian29.453.2451.151.506.0214.104.7811.295.200.460.5016.657.343.015.665
25% percentile16.712.0730.040.853.865.6751.605.0101.670.881.0121.008.242.264.273
75% percentile37.0310.4262.282.3710.0223.556.4415.759.781.752.0723.409.724.177.318

EtanerceptMedian32.704.2967.201.887.869.3611.8013.806.190.681.195.256.343.294.960
25% percentile22.621.7953.700.574.454.443.779.301.821.161.6921.008.191.823.890
75% percentile40.147.7577.103.0413.324.8036.3021.9010.601.425.4923.0011.303.985.930

CertolizumabMedian27.304.9139.301.204.9112.359.1110.883.360.481.1816.936.792.316.600
25% percentile16.342.040.790.571.617.1881.150.891.052.041.5019.758.031.405.645
75% percentile44.9317.0562.202.788.8119.9839.8019.806.562.683.3922.209.603.458.260

GolimumabMedian24.092.6435.500.835.726.766.2914.307.140.230.5816.806.002.666.765
25% percentile18.750.625.7100.164.652.121.723.793.910.681.1223.556.681.676.008
75% percentile44.0811.6155.452.299.3212.4216.9516.1514.791.711.4430.539.283.156.923

Numbers indicate the median percentages and 25% and 75% percentile values within the whole T-cell population (CD4 and CD8 cells), or within CD4 cells (Th1, Th2, Th17, Treg, and ratios), or for the other markers within the CD4 or CD8 cells, as indicated.